Skip to main content
CalciMedica, Inc. logo

CalciMedica, Inc. — Investor Relations & Filings

Ticker · CALC ISIN · US38942Q2021 US Manufacturing
Open in API
Filings indexed 461 across all filing types
Latest filing 2026-05-12 Earnings Release
Country US United States of America
Listing US CALC

About CalciMedica, Inc.

https://calcimedica.com/

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for acute inflammatory and immunologic diseases. The company specializes in the inhibition of calcium release-activated calcium (CRAC) channels, a therapeutic approach designed to modulate the immune response and protect against tissue cell injury. Its lead product candidate, Auxora™, is an intravenous formulation of the proprietary small molecule CRAC channel inhibitor, zegocractin. CalciMedica is developing Auxora for the treatment of life-threatening conditions with high unmet medical needs, including acute kidney injury (AKI) with respiratory failure and acute pancreatitis (AP), for which there are currently no approved disease-modifying treatments.

Recent filings

Filing Released Lang Actions
8-K - CalciMedica, Inc. (0001534133) (Filer)
Earnings Release Classification · 85% confidence The document is a Form 8-K filed under Item 2.02 “Results of Operations and Financial Condition” and attaches a press release announcing quarterly financial results (March 31, 2026). This matches the definition of an Earnings Release (initial announcement of quarterly/periodical financial results). It is not the full interim report, but a press release of results. Q1 2026
2026-05-12 English
10-K/A - CalciMedica, Inc. (0001534133) (Filer)
Annual Report FY 2025
2026-04-30 English
S-3 - CALCIMEDICA, INC. (0001534133) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC under the Securities Act of 1933. It is a registration statement used by companies to register securities for public offering, including common stock, preferred stock, debt securities, and warrants. The document includes a prospectus describing the securities to be offered and the terms of the offering. It is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update filings.
2026-03-03 English
10-K - CALCIMEDICA, INC. (0001534133) (Filer)
Annual Report FY 2025
2026-03-03 English
8-K - CALCIMEDICA, INC. (0001534133) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The text specifically mentions that the company issued a press release announcing its financial results for the year ended December 31, 2025, and that the press release is attached as an exhibit. The document itself does not contain the full financial results or detailed financial statements but rather references the press release. The length of the document is 3670 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report (the press release) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and includes current reports like Form 8-K that announce events or releases without containing full financial data.
2026-03-03 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-06 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.